Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3938, The “Build It In America Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3937, The “Small Business Jobs Act"

Estimated Revenue Effects Of H.R. 3938, The “Build It In America Act" Scheduled For Markup By The Committee On Ways And Means On June 13, 2023

Description of H.R. 3938, The “Build It In America Act"

Estimated Revenue Effects Of H.R. 3937, The “Small Business Jobs Act" Scheduled For Markup By The Committee On Ways And Means On June 13, 2023

Description Of H.R. 3937, The “Small Business Jobs Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3799, The “Custom Health Option And Individual Care Expense Arrangement Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3798, The “Small Business Flexibility Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3801, The “Employer Reporting Improvement Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3797, The “Paperwork Burden Reduction Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3800, The “Chronic Disease Flexibility Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 1843, The “Telehealth Expansion Act Of 2023"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3796

Description Of H.R. 3799, The “Custom Health Option And Individual Care Expense Arrangement Act"

Description Of H.R. 3798, The “Small Business Flexibility Act"

Description Of H.R. 3801, The “Employer Reporting Improvement Act"

Description Of H.R. 3797, The “Paperwork Burden Reduction Act"

Description Of H.R. 3800, The “Chronic Disease Flexible Coverage Act"

Description Of H.R. 1843, The “Telehealth Expansion Act Of 2023"

Extension Of Airport And Airway Trust Fund Excise Taxes

Overview Of The Federal Tax System As In Effect For 2023

Present Law And Economic Background Relating To Pharmaceutical Manufacturers And U.S. International Tax Policy